This website uses cookies

Cookies are small text files that can be used by websites to make a user's experience more secure and to analyze traffic to the site. We use cookies for the following purposes:

- Necessary: Cookies are required to access secure areas of the website and to provide important platform notifications. The site cannot function properly without these cookies
- Statistics: Cookies are used to track device information anonymously to better understand how visitors interact with the website.

This notice applies to the following domains:

Monoclonal Antibodies and Vaccines: Emerging Myeloma Treatments

Wed, Jul 10, 2019 1:00 PM EDT{LOCAL_TZ}

Monoclonal Antibodies and Vaccines: Emerging Myeloma Treatments 
Wednesday, July 10, 2019
1:00 PM–2:00 PM (EDT)
Among the most exciting areas of myeloma research are immunotherapies—treatments that work with a patient’s immune system to fight myeloma. There are many types of immunotherapy, including several that use monoclonal antibodies. Whether used alone or in combination with drugs, monoclonal antibodies are already being used to successfully treat myeloma patients. Additionally, monoclonal antibodies that are physically merged with drugs—that is, antibody–drug conjugates—are being studied as another possible myeloma treatment approach. Another type of immunotherapy being studied is myeloma vaccines, which are designed to help a patient’s immune system more quickly and more powerfully attack myeloma cells.

In our latest webinar, our experts explain these immunotherapies: how they work, when they are used, what patients they are for, and how they are performing in clinical trials.    
David E. Avigan, MD
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Saad Z. Usmani, MD
Levine Cancer Institute/Atrium Health
Charlotte, North Carolina

There is no fee for participating in this webinar.    
Already Registered? Log In Now
Complete this form to register for the webinar.
(* indicates required field)